Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2018

Open Access 01-12-2018 | Research article

Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis

Authors: Shuanglan Xu, Jiao Yang, Shuangyan Xu, Yun Zhu, Chunfang Zhang, Liqiong Liu, Hao Liu, Yunlong Dong, Zhaowei Teng, Xiqian Xing

Published in: BMC Pulmonary Medicine | Issue 1/2018

Login to get access

Abstract

Background

To determine the association of lymphatic vessel density (LVD) with the prognosis of Asian non-small cell lung cancer (NSCLC) patients via a meta-analysis.

Methods

Eligible studies were selected by searching PubMed and EMBASE from inception to July 25, 2017. The reference lists of the retrieved articles were also consulted. The information was independently screened by two authors. When heterogeneity was significant, a random-effects model was used to determine overall pooled risk estimates.

Results

A total of 15 studies with 1075 patients were finally included in the meta-analysis. LVD was positively associated with the prognosis of NSCLC in the overall analysis (hazard ratio (HR) 1.14, 95% confidence interval (95% CI): 1.02–1.27, p = 0.000, I2 = 73.2%). Subgroup analyses were performed on 5 VEGFR-3 groups (p = 0.709, I2 = 0.0%), 3 LYVE-1 groups (p = 0.01, I2 = 86.4%), 5 D2–40 groups (p = 0.019, I2 = 66.2%), and 2 podoplanin groups (p = 0.094, I2 = 64.5%). Sensitivity analysis indicated robust results. There was no publication bias.

Conclusions

LVD is an indicator of poor prognosis in Asian NSCLC patients.
Literature
1.
2.
3.
Li J, Li D, Wei X, Su Y. In silico comparative genomic analysis of two non-small cell lung cancer subtypes and their potentials for cancer classification. Cancer Genomics Proteom. 2014;11:303–10.
4.
5.
6.
7.
8.
9.
10.
Pappas A, Lagoudianakis E, Seretis C, Koronakis N, Keramidaris D, Grapatsas K, et al. Role of lymphatic vessel density in colorectal cancer: prognostic significance and clinicopathologic correlations. Acta Gastroenterol Belg. 2015;78:223–7.PubMed
11.
Niemiec JA, Adamczyk A, Ambicka A, Mucha-Małecka A, Wysocki WM, Biesaga B, et al. Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer. Am J Transl Res. 2017;9:1435–47.PubMedPubMedCentral
12.
13.
Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006;126:2167–77.CrossRefPubMed
14.
Waś H. Characterization of markers and growth factors for lymphatic endothelium. Postepy Biochem. 2005;51:209–14.PubMed
15.
Lingtong W, Qiangxiu W. Lymphatic endothelium-specific markers: A Systematic Review. Shandong Med. 2008;48:114–5.
16.
YU S, Binquan W. Lymphatic endothelium-specific markers. A Systematic Review. J Shanxi Med Univ 2007;03:274–77.
17.
Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789–801.CrossRefPubMedPubMedCentral
18.
Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434–40.CrossRefPubMed
19.
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Huygelen V, Colpaert CG, van Dam P, et al. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer. 2006;95:1362–6.CrossRefPubMedPubMedCentral
20.
Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385–94.CrossRefPubMedPubMedCentral
21.
Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98:769–78.CrossRefPubMed
22.
Zhang BC, Guan S, Zhang YF, Yao GQ, Yang B, Zhao Y, et al. Peritumoral lymphatic microvessel density is related to poor prognosis in lung adenocarcinoma: a retrospective study of 65 cases. Exp Ther Med. 2012;3:636–40.CrossRefPubMedPubMedCentral
23.
24.
25.
Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, et al. Relationship between serum level of lymphatic vessel endothelial hyaluronan Receptor-1 and prognosis in patients with lung cancer. J Cancer. eCollection. 2014;2014(5):242–7. https://​doi.​org/​10.​7150/​jca.​8486.CrossRef
26.
Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668–77.CrossRefPubMed
27.
Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457–64.CrossRefPubMed
28.
29.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
30.
Leonard T, Duffy JC. A Bayesian fixed effects analysis of the mantel-Haenszel model applied to meta-analysis. Stat Med. 2002;21:2295–312.CrossRefPubMed
31.
Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443–57.CrossRefPubMed
32.
33.
34.
35.
36.
37.
38.
39.
40.
Ohta Y, Shimizu Y, Minato H, Matsumoto I, Oda M, Watanabe G. Results of initial operations in non-small cell lung cancer patients with single-level N2 disease. Ann Thorac Surg. 2006;81:427–33.CrossRefPubMed
41.
Chen F, Takenaka K, Ogawa E, Yanagihara K, Otake Y, Wada H, et al. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res. 2004;10:8548–53.CrossRefPubMed
42.
43.
Zheng CL, Qiu C, Shen MX, Qu X, Zhang TH, Zhang JH, et al. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis. Asian Pac J Cancer Prev. 2015;16:1881–95.CrossRefPubMed
44.
Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001;85:255–60.CrossRefPubMedPubMedCentral
45.
46.
Chang C, Wang P, Yang H, Li L, Zhang LB. Expression of LYVE-1 and Prox-1 in non-small cell lung cancer and the relationship with lymph node metastasis. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42:174–8.PubMed
Metadata
Title
Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis
Authors
Shuanglan Xu
Jiao Yang
Shuangyan Xu
Yun Zhu
Chunfang Zhang
Liqiong Liu
Hao Liu
Yunlong Dong
Zhaowei Teng
Xiqian Xing
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2018
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-018-0702-9

Other articles of this Issue 1/2018

BMC Pulmonary Medicine 1/2018 Go to the issue

Research article

Pleural infection: a retrospective study of clinical outcome and the correlation to known etiology, co-morbidity and treatment factors

Research article

Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series

Research article

The cutoff point of clinical chronic obstructive pulmonary disease questionnaire for more symptomatic patients

Research article

Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review

Research article

Morbidity and mortality related to pneumonia and TRACHEOBRONCHITIS in ICU after lung transplantation

Research article

Pulmonary arterial hypertension in Latin America: epidemiological data from local studies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits